These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26795258)

  • 1. Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know.
    Forsmark CE
    Pancreatology; 2016; 16(1):10-3. PubMed ID: 26795258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
    Giorda CB; Picariello R; Nada E; Tartaglino B; Marafetti L; Costa G; Gnavi R
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):111-5. PubMed ID: 24622714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
    Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
    Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?
    Lamont BJ; Andrikopoulos S
    J Endocrinol; 2014 Apr; 221(1):T43-61. PubMed ID: 24424288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
    Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
    de Heer J; Göke B
    Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
    Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
    N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
    [No Abstract]   [Full Text] [Related]  

  • 11. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
    Roshanov PS; Dennis BB
    Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 13. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.
    Giorda CB; Nada E; Tartaglino B; Marafetti L; Gnavi R
    Diabetes Obes Metab; 2014 Nov; 16(11):1041-7. PubMed ID: 24702687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.
    Azoulay L
    Diabetes Care; 2015 Jun; 38(6):951-3. PubMed ID: 25998285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?
    Sohani ZN; Li L; Sun X
    Diabetes Res Clin Pract; 2016 Jul; 117():28-31. PubMed ID: 27329019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies.
    Boniol M; Franchi M; Bota M; Leclercq A; Guillaume J; van Damme N; Corrao G; Autier P; Boyle P
    Diabetes Care; 2018 Feb; 41(2):286-292. PubMed ID: 29146599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
    Nauck MA; Meier JJ; Schmidt WE
    Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
    [No Abstract]   [Full Text] [Related]  

  • 18. Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
    Cox AR; Lam CJ; Rankin MM; Rios JS; Chavez J; Bonnyman CW; King KB; Wells RA; Anthony D; Tu JX; Kim JJ; Li C; Kushner JA
    Endocrinology; 2017 Jun; 158(6):1701-1714. PubMed ID: 28323942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin based therapy and pancreatic cancer: Realising the reality.
    Suryadevara V; Roy A; Sahoo J; Kamalanathan S; Naik D; Mohan P; Kalayarasan R
    World J Gastroenterol; 2022 Jul; 28(25):2881-2889. PubMed ID: 35978867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database.
    Soranna D; Bosetti C; Casula M; Tragni E; Catapano AL; Vecchia CL; Merlino L; Corrao G
    Diabetes Res Clin Pract; 2015 May; 108(2):243-9. PubMed ID: 25748827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.